The revenue beat and debt retirement are clear positives, but the widened net loss and cash burn warrant caution. With a $13M market cap and limited cash runway, the next quarter's cash flow statement and any additional financing needs will be critical. Monitor the Q3 earnings call for operating leverage progress.
Price Chart
Executive Summary
Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31% consumables growth and 27% flow cell sales growth. The company fully retired its secured convertible debentures, eliminating all secured debt. However, net loss widened to $7.4M from $6.9M, and the company remains unprofitable with ongoing cash burn.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $8.2M, +21% YoY (vs $6.7M in Q2 2025)
- Consumables revenue $4.3M, +31% YoY
- 9,219 nanochannel array flow cells sold, +27% YoY
- Gross margin improved to 53% from 52%
- Operating loss improved to -$7.2M from -$7.8M
- Net loss widened to -$7.4M from -$6.9M (due to non-operating items)
- Full retirement of all outstanding Senior Secured Convertible Debentures
- Q3 2026 revenue guidance: $8.2M to $8.6M
- FY2026 revenue guidance maintained at $31M to $33M (low end raised from $30M)
- Cash and investments (incl. restricted) fell to $10.4M from $29.5M at Dec 2025, largely due to debt retirement
Financial Impact
Revenue beat company guidance by ~5-9% ($8.2M vs $7.5-7.8M). Debt retirement removes $10M in current liabilities and liens on assets.
Risk Factors
- Continued net losses and negative operating cash flow
- Cash and investments of $10.4M may not sustain operations for more than a few quarters without additional funding
- Going concern risk highlighted in forward-looking statements
- Low market cap ($13M) and thin trading volumes could amplify volatility
- Dependence on adoption of OGM technology in a competitive market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001411690-26-000043 |
| Document: bngo-20260810.htm | 0001411690-26-000043 |
| Document: 0001411690-26-000043-index-headers.html | 0001411690-26-000043 |
| Document: 0001411690-26-000043-index.html | 0001411690-26-000043 |
| Document: 0001411690-26-000043.txt | 0001411690-26-000043 |
| 8-K Data (Synthetic) | 0001411690-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $1.22 $1.16 | ▼ −4.92% | ▼ −4.77% | $1.20 (−1.64%) |
Sep 14, 2026 6w ago | Press Release | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.20 (−9.77%) |
Sep 14, 2026 6w ago | 8-K | $1.33 $1.83 | ▲ +37.59% | ▲ +37.49% | $1.20 (−9.77%) |
Aug 10, 2026 11w ago | 8-K | $1.19 $1.18 | ▼ −0.84% | ▼ −0.44% | $1.20 (+0.84%) |
Jun 5, 2026 20w ago | 8-K | $1.17 $1.16 | ▲ +0.85% | ▲ +2.97% | $1.20 (−2.56%) |
May 28, 2026 21w ago | 8-K | $1.25 $1.30 | ▲ +4.00% | ▲ +4.05% | $1.20 (−4.00%) |
Mar 23, 2026 31w ago | Press Release | $1.18 $1.17 | ▲ +0.85% | ▲ +0.42% | $1.20 (−1.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers